MYGN Myriad Genetics, Inc.
Myriad Genetics, Inc. (MYGN) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $66.8K.
Where they traded
Last open-market purchase: May 14, 2026 , by Bisaro Paul .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Kumar Rashmi | Director | Sell 10b5-1 | 15,000 | $4.46 | $66.8K | 171,889 −8% of holding | |
| Bisaro Paul | Director | Buy | 7,500 | $3.69 | $27.6K | 97,441 | |
| Raha Samraat S. | President and CEO | Buy | 40,000 | $5.00 | $199.8K | 493,104 | |
| Phanstiel S. Louise | Director | Buy | 48,000 | $4.66 | $223.7K | 281,951 | |
| Phanstiel S. Louise | Director | Buy | 50,407 | $4.80 | $242.1K | 233,951 | |
| Phanstiel S. Louise | Director | Buy | 6,100 | $4.74 | $28.9K | 183,544 |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.